Journal: Frontiers in Aging Neuroscience

Article Title: A Multi-Ingredient Nutritional Supplement in Combination With Resistance Exercise and High-Intensity Interval Training Improves Cognitive Function and Increases N -3 Index in Healthy Older Men: A Randomized Controlled Trial

doi: 10.3389/fnagi.2019.00107

Figure Lengend Snippet: Experimental design. Participants consumed either an experimental supplement (SUPP) or control (CON) beverage twice per day for 20 weeks (weeks 0–19, inclusive). Between weeks 7–18 (inclusive), participants completed a 12-week exercise training program. Exercise training consisted of RET twice weekly (Mondays and Fridays) and HIIT once per week (Wednesdays). At weeks –1 (baseline), 6, and 19 we assessed cognitive function and obtained a blood sample for the measurement of BDNF, 25(OH)D, and erythrocyte plasma membrane phospholipid composition. Phase 1: SUPP/CON took place between weeks 0–6, and Phase 2: SUPP/CON + EX took place between weeks 7–19. SUPP, supplement; CON, control; RET, resistance exercise training; HIIT, high-intensity interval training; BDNF, brain-derived neurotrophic factor; 25(OH)D, 25-hydroxyvitamin D.

Article Snippet: Fasting plasma 25(OH)D concentrations were measured by radioimmunoassay (DiaSorin Canada Inc.; Mississauga, ON, Canada), and fasting plasma BDNF concentrations were measured using a Quantikine Human Free BDNF ELISA kit (R&D Systems, Inc.; Minneapolis, MN, United States).

Techniques: Control, Clinical Proteomics, Membrane, Derivative Assay

Journal: Frontiers in Aging Neuroscience

Article Title: A Multi-Ingredient Nutritional Supplement in Combination With Resistance Exercise and High-Intensity Interval Training Improves Cognitive Function and Increases N -3 Index in Healthy Older Men: A Randomized Controlled Trial

doi: 10.3389/fnagi.2019.00107

Figure Lengend Snippet: Blood analyses and nutrient bioavailability.

Article Snippet: Fasting plasma 25(OH)D concentrations were measured by radioimmunoassay (DiaSorin Canada Inc.; Mississauga, ON, Canada), and fasting plasma BDNF concentrations were measured using a Quantikine Human Free BDNF ELISA kit (R&D Systems, Inc.; Minneapolis, MN, United States).

Techniques: Clinical Proteomics, Membrane

Journal: Journal of Perinatal Medicine

Article Title: Nicotine affects the expression of brain-derived neurotrophic factor mRNA and protein in the hippocampus of hypoxic newborn piglets

doi: 10.1515/jpm.2009.081

Figure Lengend Snippet: Figure 1 Relative expression of BDNF mRNA in hippocampus. The group treated with nicotine 130 mg/kg/h show a significant increase in BDNF mRNA expression compared to the group treated with saline. 1snicotine 130 mg/kg/h; 2snicotine 260 mg/kg/h; 3sadrena- line 0.05 mg/kg/minqsaline; 4ssaline. *Ps0.038 for nicotine 130 mg/kg/h vs. saline.

Article Snippet: Monoclonal anti-human BDNF antibody titer 1:25 (Clone 35928; R&D Systems, Minneapolis, MN, USA) was used as primary antibody.

Techniques: Expressing, Saline

Journal: Journal of Perinatal Medicine

Article Title: Nicotine affects the expression of brain-derived neurotrophic factor mRNA and protein in the hippocampus of hypoxic newborn piglets

doi: 10.1515/jpm.2009.081

Figure Lengend Snippet: Figure 4 Immunohistochemistry of BDNF protein, nicotine vs. saline. Pictures from the dentate gyrus 20=enlarged. A is from an ani- mal treated with nicotine 130 mg/kg/h; B is from an animal treat- ed with saline; picture A presents a larger number of BDNF positive cells than picture B.

Article Snippet: Monoclonal anti-human BDNF antibody titer 1:25 (Clone 35928; R&D Systems, Minneapolis, MN, USA) was used as primary antibody.

Techniques: Immunohistochemistry, Saline

Journal: Journal of Perinatal Medicine

Article Title: Nicotine affects the expression of brain-derived neurotrophic factor mRNA and protein in the hippocampus of hypoxic newborn piglets

doi: 10.1515/jpm.2009.081

Figure Lengend Snippet: Figure 2 Box plot of % BDNF positive cells in the dentate gyrus of the hippocampus. There are significantly more BDNF positive cells in the dentate gyrus of the animals treated with nicotine 130 mg/kg/h com- pared to the saline treated animals. *Ps0.009.

Article Snippet: Monoclonal anti-human BDNF antibody titer 1:25 (Clone 35928; R&D Systems, Minneapolis, MN, USA) was used as primary antibody.

Techniques: Saline

Journal: Journal of Perinatal Medicine

Article Title: Nicotine affects the expression of brain-derived neurotrophic factor mRNA and protein in the hippocampus of hypoxic newborn piglets

doi: 10.1515/jpm.2009.081

Figure Lengend Snippet: Figure 3 Immunohistochemistry of BDNF protein. Picture from the dentate gyrus 40=enlarged. The cells with the large, dark brown nucleuses are positive (black arrows), the cells with light brown or blue nucleuses are negative (open arrows).

Article Snippet: Monoclonal anti-human BDNF antibody titer 1:25 (Clone 35928; R&D Systems, Minneapolis, MN, USA) was used as primary antibody.

Techniques: Immunohistochemistry

Journal: Acta neuropathologica communications

Article Title: BDNF augmentation reverses cranial radiation therapy-induced cognitive decline and neurodegenerative consequences.

doi: 10.1186/s40478-024-01906-9

Figure Lengend Snippet: Fig. 2 Riluzole treatment restores hippocampal BDNF in the irradiated hippocampus. 10–12 weeks old WT male mice received cranial radiation therapy (RT) followed by riluzole (RZ) treatment (13 mg/kg) in drinking water for 6–7 weeks. An ELISA-based quantification of BDNF from the micro-dissected hippocampus showed RT-induced reductions in the RT + Vehicle group. Importantly, RZ treatment in the cranially irradiated mice showed significant restoration of BDNF levels. Data are presented as mean ± SEM (N = 6–10 mice per group). P values were derived from two-way ANOVA and Bonferroni’s multiple comparisons test

Article Snippet: BDNF levels were quantified using a commercially available ELISA kit (E-EL-M0203, Elabscience Biotechnology) and uncoated ELISA plates (Nunc MaxiSorp, Biolegend).

Techniques: Irradiation, Enzyme-linked Immunosorbent Assay, Derivative Assay

Journal: International journal of molecular medicine

Article Title: Involvement of brain-derived neurotrophic factor in exercise‑induced cardioprotection of post-myocardial infarction rats.

doi: 10.3892/ijmm.2018.3841

Figure Lengend Snippet: Figure 4. Serum BDNF level is associated with myocardium angiogenesis and left ventricle function. (A) ELISA measurements of the serum BDNF con- centration at the (a) beginning and the (b) end of the exercise programme. *P<0.05 vs. Sham and †P<0.05 vs. MIC. (B) The serum BDNF concentration was positively correlated with myocardial microvessel density (r=0.542, P=0.006). (C) The serum BDNF concentration was positively correlated with the EF (r=0.631, P=0.001). (D) A positive correlation was identified between improved serum BDNF levels and the EF (r=0.502, P=0.013). The values are presented as the mean ± standard error of the mean (n=8). MI, myocardial infarction; L‑NAME, NG‑nitro‑L‑arginine methyl ester; MIC, sedentary MI group; MIE, MI + exercise group; MIE+L, MI + exercise + L‑NAME group; BDNF, brain‑derived neurotrophic factor; EF, ejection fraction; HPF, high‑powered fields.

Article Snippet: Serum and media BDNF concentrations were detected using an ELISA kit (cat. no. DBNT00; R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay

Journal: International journal of molecular medicine

Article Title: Involvement of brain-derived neurotrophic factor in exercise‑induced cardioprotection of post-myocardial infarction rats.

doi: 10.3892/ijmm.2018.3841

Figure Lengend Snippet: Figure 5. SS of 12 dyn/cm2 increased BDNF/TrkB‑FL protein levels and sustained TrkB‑FL activation in HUVECs. (A) Representative western blot analysis images for BDNF and the protein level analysis in HUVECs exposed to SS (*P<0.01 vs. Ctrl). (B) ELISA measurement of BDNF levels in the culture medium following exposure of HUVECs for 1, 3, 6 and 12 h of SS (*P<0.01 vs. Ctrl). (C) Representative western blot analysis images for TrkB‑FL and the protein level analysis in HUVECs exposed to SS (*P<0.01 vs. Ctrl). (D) TrkB‑T protein expression and phosphorylation levels were not modified by SS at 12 dyn/cm2. (E) Representative western blot analysis images for phosphorylated TrkB‑FL and the protein level analysis in HUVECs exposed to SS (**P<0.001 vs. Ctrl). (F) TrkB‑T phosphorylation levels were not modified by SS at 12 dyn/cm2. The values are presented as the mean ± standard error of the mean (n=6). SS, shear stress; BDNF, brain‑derived neurotrophic factor; TrkB, BDNF/NT‑3 growth factors receptor; FL, full‑length; T, truncated; p, phosphorylated; ctrl, control; HUVECs, human umbilical vein endothelial cells; t, time.

Article Snippet: Serum and media BDNF concentrations were detected using an ELISA kit (cat. no. DBNT00; R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's protocol.

Techniques: Activation Assay, Western Blot, Enzyme-linked Immunosorbent Assay, Expressing, Phospho-proteomics, Modification, Shear, Control

Journal: International Journal of Molecular Sciences

Article Title: Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner

doi: 10.3390/ijms21093079

Figure Lengend Snippet: Fingolimod-phosphate (FTY720-P) regulates neuronal architecture in a BDNF-dependent manner. ( A ) Representative Neurolucida tracings, used to perform the Sholl analysis of dendritic complexity for feGFP expressing neurons treated for 24h with: DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue). Scale bar: 100 μm. ( B ) Sholl analysis displayed as number of dendritic intersections against distance from the cell body for DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue) and ( C ) total dendritic complexity of all treatment groups. F value in ( B ) refers to comparison between all the 4 treatment groups. ( D ) Dendritic spine densities for DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue) calculated using segments of secondary dendritic branches as shown in ( E ) feGFP panel. The Syn panel displays the corresponding staining of the pre-synaptic marker SynapsinI/II and the merge panel shows the images with overlapping SynapsinI/II puncta (red, pre-synapse) to its matching feGFP dendrite segment (green, post-synapse). The arrows point to coinciding puncta, indicative of mature synapse between the post and pre-synaptic compartments. Scale bar: 5μm. ( F ) The graph compares the fraction of SynapsinI/II positive feGFP labelled spines for DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue). ( G ) Representative fields of view (FOV) of the DMSO, 2nM FTY720-P, DMSO + TrkBFc and 2nM FTY720-P + TrkBFc treated hippocampal cultures stained for c-fo s . Scale bar: 100μm. ( H ) Quantification of the proportion of c-Fos expressing neurons represented as normalized fraction for DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue) treated cultures. All graphs represent data as mean + SEM. Numbers in the bars show either total number of neurons or of FOV analyzed, obtained from ≥3 sets of independent experiments. Two-way ANOVA followed by Bonferroni post-hoc test was used in ( B ). For ( C , D , F ) and ( H ) one-way ANOVA with Bonferroni post-hoc was used. Denotations for significance are * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: Recombinant Human BDNF protein (R&D systems, Minneapolis, MN, USA) was dissolved in sterile PBS with 0.1% BSA at a concentration of 50 ng/μL.

Techniques: Expressing, Comparison, Staining, Marker

Journal: International Journal of Molecular Sciences

Article Title: Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner

doi: 10.3390/ijms21093079

Figure Lengend Snippet: Treatment with the non-phosphorylated Fingolimod (FTY720) modulates neuronal architecture. ( A ) | Representative Neurolucida tracings from feGFP positive hippocampal neurons used for the Sholl analysis from cultures treated either with DMSO or 10nM FTY20 for 24 h. Scale bar: 100μm. ( B ) | Dendritic complexity shown by the number of dendritic intersections plotted against the distance from the soma for DMSO (black) and FTY720 (blue) treated neurons. The F value shows the statistical comparison between the two groups. The inset graph represents total dendritic complexity upon treatment with DMSO (black) and FTY720 (blue). ( C ) | Total dendritic length for DMSO (black) and FTY720 (blue) treated neurons. ( D ) | Representative stretches from dendrites of eGFP transfected hippocampal neurons showing dendritic spine protrusions, treated either with DMSO or FTY720 for 24h. Scale bar: 5μm. ( E ) | The graph shows dendritic spine density for DMSO (black) and FTY720 (blue) treated neurons . ( F ) | Representative images of fields of view (FOV) from primary hippocampal cultures stained with anti phospho-ERK1/2 antibody, 30 min post-application of one of the following: DMSO, 10nM FTY720, DMSO_100, 100nM FTY720, DMSO_100 + TrkB-Fc, 100nM FTY720 + TrkB-Fc or 40ng recombinant BDNF protein as a positive control. Scale bar: 100μm. ( G ) | The graph displays the fraction of pERK1/2 expressing neurons relative to the total number of MAP2 + neurons. The data is normalized to the respective controls and compared between the different treatment groups: DMSO (black), 10nM FTY720 (light blue solid), DMSO100 (gray), 100nM FTY720 (dark blue solid), 40ng recombinant BDNF (magenta), DMSO100 + TrkB-Fc (gray open), 100nM FTY720 + TrkB-Fc (dark blue open). All data is plotted as mean + SEM. Numbers in the bars show total number of neurons or FOV analyzed, obtained from ≥3 sets of independent experiments. Two-way ANOVA followed by Bonferroni post-hoc test was used in ( B ). For ( B ) total intersections, ( C ) and ( E ) unpaired Student’s t-test and for ( G ) one-way ANOVA with Bonferroni post-hoc was used. Denotations for significance are * p < 0.05, *** p < 0.001, **** p < 0.0001.

Article Snippet: Recombinant Human BDNF protein (R&D systems, Minneapolis, MN, USA) was dissolved in sterile PBS with 0.1% BSA at a concentration of 50 ng/μL.

Techniques: Comparison, Transfection, Staining, Recombinant, Positive Control, Expressing